control rat pulmonary artery smooth muscle cells rpasmcs  (Cell Applications Inc)

Journal: bioRxiv

Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

doi: 10.64898/2026.01.05.697826

Figure Lengend Snippet: A , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group, as measured using the CCK-8 assay. B , rPSAMCs stained with Hoechst dye 72 h after siRNA transfection. C , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after siRNA transfection. D , Proliferative capacity of rPASMCs in the hnRNPA1 siRNA-treated group compared with the negative control siRNA-treated group via Ki-67 staining. E , Apoptosis of rPASMCs evaluated by cleaved caspase 3 expression in the hnRNPA1 siRNA-treated group compared with that in the negative control siRNA-treated group by staining for cleaved caspase 3. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.

Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: Negative Control, CCK-8 Assay, Staining, Transfection, Expressing, Control, Cell Counting, Small Interfering RNA

Journal: bioRxiv

Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

doi: 10.64898/2026.01.05.697826

Figure Lengend Snippet: A , hnRNPA1, IQGAP1, PKM2 and β-actin protein expression in normal rPASMCs and hypoxia-treated rPASMCs treated with negative control siRNA or hnRNPA1 siRNA. B–D , Ratio of hnRNPA1/β-actin (B) PKM2/β-actin (C) and IQGAP1/β-actin (D) in normal rPASMCs and hypoxia-treated rPASMCs treated with negative control or hnRNPA1 siRNAs. Orange, yellow, blue, and green colors show normoxia + control siRNA, normoxia + hnRNPA1 siRNA, hypoxia + control siRNA, and hypoxia + hnRNPA1 siRNA, respectively. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 6 per group. hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; IQGAP1, IQ motif containing GTPase activating protein 1; PKM2, pyruvate kinase M 2; rPASMC, rat pulmonary artery smooth muscle cell; siRNA, small interfering RNA.

Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: Expressing, Negative Control, Control, Small Interfering RNA

Journal: bioRxiv

Article Title: Heterogeneous Nuclear Ribonucleoprotein A1 as a Key Regulator in Pulmonary Arterial Hypertension Development

doi: 10.64898/2026.01.05.697826

Figure Lengend Snippet: A , hnRNPA1 and β-actin protein expression in hypoxia-treated rPASMCs treated with tetracaine. B , Ratio of hnRNPA1/β-actin in hypoxia-treated rPASMCs treated with tetracaine. C , Proliferative capacity of hypoxia-treated rPASMCs treated with tetracaine, measured via the CCK-8 assay. D , rPSAMCs stained with Hoechst dye 72 h after tetracaine treatment. E , Number of rPASMCs adhering to the bottom of 96-well plates 72 h after tetracaine treatment. * P < 0.05; ** P < 0.01. Statistical analysis was performed using the Wilcoxon signed-rank test. Values are the mean ± SE, n = 3 per group. CCK, cell counting kit; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; rPASMC, rat pulmonary artery smooth muscle cell.

Article Snippet: Control rat pulmonary artery smooth muscle cells (rPASMCs) were purchased from Cell Applications, USA (Cat# CAR35205a) and cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and 1% penicillin–streptomycin in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: Expressing, CCK-8 Assay, Staining, Cell Counting

Journal: bioRxiv

Article Title: Impaired Lung BCAA Metabolism Promotes Ferroptosis and Resultant Pulmonary Arterial Hypertension-Associated Hepatopathy

doi: 10.1101/2025.09.03.672819

Figure Lengend Snippet: Excess BCAAs promoted a pro-ferroptotic phenotype in human PASMC . (A) Representative confocal micrographs of PASMC stained with MitoTracker Orange and quantification of mitochondrial organization in control and BCAA-treated PASMC (Control PASMC [Con]: 1.1±0.6, BCAA-Treated PASMC [BCAA]: 0.7±0.3); p -values determined by Mann-Whitney U-test. (B) Confocal micrographs of TRME-stained PASMC in control and BCAA-treated media, with corresponding quantification of mitochondrial membrane hyperpolarization, indicated by fluorescence intensity (Con: 8.3±17.2, BCAA: 42.7±9.7). p -values determined by Mann-Whitney U-test. (C) Excess BCAAs increase mitochondrial ROS, demonstrated by confocal micrographs of control and BCAA-treated PASMCs stained with MitoSox Red (Con: 6.4±2.1, BCAA: 14.5±6.9 MFI). p -values determined by Mann-Whitney U-test. (D) Representative confocal micrographs of control, BCAA-treated, and BCAA and ferrostatin-1-treated PASMCs incubated with 50 μM oleate and 50 μM palmitate and stained for lipid peroxidation using BODIPY (Con: 1.8±0.3, BCAA: 1.4±0.1, BCAA-treated with 5 μM ferrostatin-1 [BCAA-FER1]: 1.7±0.3). p -values determined by Kruskal-Wallis test and Dunn’s multiple comparisons test. (E) Incubation with BCAAs induces ferroptotic cell death, demonstrated by viability staining of control, BCAA-treated, and BCAA-treated with ferrostatin-1 PASMCs via Trypan Blue (Con: 9.4±7.5, BCAA: 31.7±11.7, BCAA-FER1: 13.0±11.1). White arrows indicate trypan blue-positive cells. p -values determined by ordinary one-way ANOVA with Tukey’s multiple comparison test.

Article Snippet: Human PASMC (ATCC PCS-100-023) were grown with Sigma Basic Eagle Medium (Sigma, B1522-500) with supplements (Lonza, CC-3182) and passaged with subculture reagents (Lonza CC-5034).

Techniques: Staining, Control, MANN-WHITNEY, Membrane, Fluorescence, Incubation, Comparison